Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers

EBioMedicine

D. Gareth Evans¹  Ping-Cheng Yi²  Yang Pan²  Louis Dubeau³  Mark Cline⁴  Charles E. Wood⁴  Adam N. Rosenthal⁵  Matthew Burnell⁵  Sue Philpott⁵  Daniel Reisel⁵  Martin Widschwendter⁵  Ian J. Jacobs⁵  Usha Menon⁵  Lindsay Fraser⁵  William C. Dougall⁶ 

[1] Department of Genomic Medicine, Institute of Human Development, University of Manchester, St. Mary's Hospital, Manchester M13 9WL, UK;Department of Molecular Sciences, Amgen Inc, Seattle, WA 98119, USA;Department of Pathology, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA;Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA;Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, 74 Huntley Street, London WC1E 6AU, UK;Therapeutic Innovation Unit (TIU), Amgen Inc., Seattle, WA 98119, USA;

关键词: Breast cancer;    BRCA1 and BRCA2 mutations;    RANKL;    OPG;    Carcinogenesis;    Cancer prevention;   

DOI  :  10.1016/j.ebiom.2015.08.037

来源: DOAJ

【 授权许可】

Unknown